Recent studies indicate that the pro-inflammatory action of aldosterone (ALDO) or the activation of mineralocorticoid receptors contribute to the increased risk of cardiovascular disease (CVD). The aim of the present study was to investigate the grade of the inflammatory activation, in relation to ALDO levels, in a large cohort of essential hypertensive patients. The study included 3770 consecutive essential hypertensive patients who attended our outpatient clinics. Patients were evaluated with medical history, repeated office blood pressure and 24-h ambulatory blood pressure monitoring (ABPM), physical examination and full laboratory assessment including ALDO in 24-h urine collection, plasma renin activity (PRA), high-sensitivity C-reactive protein (hsCRP), total fibrinogen, serum homocysteine (Hcy), serum amyloid A (SAA) and white blood cells (WBC) measurements in morning blood samples. Patients were divided according to PRA (high PRA 41 ng ml À 1 h À 1 , low PRA o1 ng ml À 1 h À 1 ) and ALDO levels (high ALDO 412 but o24 mg per 24 h, low ALDO o12 mg per 24 h) in four groups. The hsCRP (Po0.022) and SAA (Po0.001) levels increased in parallel with the ALDO metabolism. Similar differences were observed for Hcy (Po0.001), fibrinogen (P ¼ 0.001) and WBC (Po0.02). High ALDO levels within normal range are related to the presence of subclinical inflammation in essential hypertension. These data indicate that ALDO and PRA influence the process of subclinical inflammation involved in the increased risk of CVD.
INTRODUCTION
Aldosterone (ALDO), a major component of the renin-angiotensin aldosterone system (RAAS), is a regulator of renal sodium and potassium handling, blood volume and blood pressure. 1 Furthermore, it has been recognized as one of the key hormones in pathophysiology, not only in primary aldosteronism, but also in essential hypertension. 2 Recent studies suggest that elevated ALDO biosynthesis, as defined by an increased ALDO-to-renin ratio, is present in up to 15% of essential hypertensives. 3 Clinically, ALDO receptor antagonism protects against cardiovascular and renal remodeling, independently of major alterations in blood pressure or NaCl homeostasis. 4, 5 Low grade inflammation localized in the vascular endothelium is emerging as an important factor in the pathophysiology of hypertension, 6 or the initiation and progression of atherosclerosis as well as for arterial stiffness increase and development of cardiovascular disease. [7] [8] [9] Patients with cardiovascular disease present with increased expression as well as plasma concentrations of inflammatory markers and mediators. 10, 11 Among them, C-reactive protein (CRP) has been demonstrated as an independent risk factor for the development of hypertension. 12 The aim of the study was to investigate the grade of subclinical inflammation, reflected by high-sensitivity CRP (hsCRP), homocysteine, serum amyloid A, white blood cells (WBC) and fibrinogen and plasminogen activator inhibitor-1 (PAI-1), in relation to ALDO and plasma renin activity (PRA) levels, in a large number of essential hypertensive patients.
MATERIALS AND METHODS Participants
We studied 3770 consecutive patients (mean age 55 years old) who attended our outpatient clinics. The inclusion criteria were patients with uncomplicated essential hypertension, never treated, with office systolic blood pressure 4140 mm Hg and/or office diastolic blood pressure 490 mm Hg in three consecutive visits to our clinic, one week apart and mean 24-h ambulatory blood pressure monitoring (ABPM) values 4125/ 80 mm Hg, using a Spacelabs 90207 device (Spacelabs Inc, Redmond, WA, USA). All patients included in the study were subjected to physical examination, medical history assessment and blood sampling for laboratory examinations.
Exclusion criteria
Patients with clinical and/or laboratory findings of primary or secondary aldosteronism (urinary ALDO 424 mg per 24 h), endocrine disorders, chronic pulmonary disease, renal failure (serum creatinine 41.4 mg dl À 1 ), symptomatic coronary artery disease or heart failure, ventricular arrhythmias, sinus bradycardia (o55 bpm), sinus tachycardia (4100 bpm) or atrioventricular conduction disturbance and patients with acute or chronic inflammatory diseases or under anti-inflammatory medications were excluded from the study. All participants underwent full laboratory evaluation and supplementary test for secondary hypertension according to the European Society of Hypertension and the European Society of Cardiology Guidelines for the management of arterial hypertension. 13, 14 The study participants were enrolled between 2000 and 2012. The study protocol was reviewed and approved by the Ethics Committee of Hippokration Hospital in respect of the Helsinki Declaration. 1 Hypertensive Unit, 1st Cardiology Clinic, Athens University, Hippokration Hospital, Athens, Greece and Laboratory measurements and grouping of the high and low ALDO components Blood samples were collected from the antecubital vein between 0800 and 1000 hours, with the patient in the sitting position for at least 10 min, after an overnight fast and at least 12 h alcohol abstinence. The walk time to the lab was negligible. All tests were carried out in the same laboratories using the criteria of the World Health Organization.
Furthermore, an early morning (0800-1000 hours) ambulant PRA test was carried out using radioimmunoassay of angiotensin I after timed incubation of plasma under optimized conditions to classify patients with high PRA and low PRA (cutoff limit of 1 ng ml
, and 24-h urine collection for ALDO was used to classify patients with low ALDO o12 mg per 24 h and high ALDO 412 but o24 mg per 24 h.
Statistics
Continuous variables are presented as mean values±s.d., whereas qualitative variables are presented as absolute and relative frequencies. Univariate analysis was applied to assess the associations of ALDO and PRA levels to inflammatory markers. Comparisons between normally distributed continuous variables were made using the Student's t-test, whereas for discrete variables w 2 test was applied. One-way analysis of variance was used also for comparisons of continuous variables between the four groups. Exploratory post-hoc analyses were performed with Bonferroni's adjustment for multiple comparisons.
Multivariable analysis with linear regression analysis was performed adjusting for multiple risk factors and the results obtained from the regression models are presented as b-coefficients and the 95% confidence intervals. STATA 8.0 software (Stata Corporation 2003, TX, USA) was used for all statistical calculations. A P-value o0.05 was considered statistically significant.
RESULTS
Overall, the study population was divided into four groups according to 24-h ALDO and PRA levels: group I (n ¼ 778, high 24-h ALDO and low PRA), group II (n ¼ 976, high 24-h ALDO and high PRA), group III (n ¼ 1016, low 24-h ALDO and low PRA) and group IV (n ¼ 1000, low 24-h ALDO and high PRA). Patient characteristics are presented in Table 1 . The analysis of variance among the four groups revealed higher levels of inflammatory markers and prothrombotic indices in the high 24-h ALDO groups in comparison to the low 24-h ALDO groups (group I and II vs III and IV).
Comparing the four study groups, significant differences were found in gender (Po0.001), age (Po0.001), smoking habit (Po0.001), BMI (Po0.001), total cholesterol (P ¼ 0.006), triglycerides (P ¼ 0.013), fasting glucose (P ¼ 0.001) and eGFR (Po0.001). Furthermore, significant differences were found in hsCRP (P ¼ 0.022), serum amyloid A (Po0.001), WBC (P ¼ 0.02), homocysteine (Po0.001), fibrinogen (P ¼ 0.001) and PAI-1 (Po0.001) as well for systolic blood pressure (Po0.001) and diastolic blood pressure (P ¼ 0.008). Group I had higher values in all the above parameters. A multivariate regression analysis was performed and the three groups (II, III and IV) were compared with group I after adjusting for age, gender, BMI, smoking, lipid profile, serum glucose levels, eGFR, systolic blood pressure and diastolic blood pressure (Table 2) .
Overall, hsCRP, serum amyloid A, homocysteine, fibrinogen and PAI-1 levels were significantly lower in groups III and IV as compared with that in group I. Specifically, homocysteine was significantly lower in groups III and IV, respectively , whereas no significant difference was revealed for WBC (P ¼ not significant).
DISCUSSION
The present study aimed to assess the association between ALDO-PRA levels, within normal range, to inflammatory and prothrombotic factors in patients with essential arterial , Na on 24-h urine collection; PAI-1, plasminogen activator inhibitor-1; PRA, plasma renin activity; SAA, serum amyloid A; SBP, systolic blood pressure; WBC, white blood cell count. Groups: I high ALDO-low PRA, II high ALDO-high PRA, III low ALDO-low PRA, IV low ALDO-high PRA.
Aldosterone and subclinical inflammation in essential hypertension V Tzamou et al hypertension. The key finding of the study is that nevertreated essential hypertensive patients with a more activated RAAS (group I high ALDO-low PRA and group II high ALDO-high PRA) present higher levels of inflammatory and prothrombotic markers. Significant differences in the studied inflammatory and prothrombotic factors were observed between the four ALDO-PRA groups, whereas after adjustment for age, gender, BMI, smoking, lipid profile, serum glucose levels, eGFR, systolic blood pressure and diastolic blood pressure, no significant difference was revealed between the groups I and II. Moreover, no significant relation was revealed for WBC between the four groups after adjustment.
The earlier data suggest that ALDO promotes inflammation and fibrosis and modulates cell proliferation. 15 Previous studies suggest that osteopontin and adiponectin are related to each other, underlying their role in the mechanisms of RAAS and inflammation. 16 Furthermore, ALDO and/or activation of the mineralocorticoid receptor contribute to cardiovascular remodeling and renal dysfunction in hypertensive patients. In addition, mineralocorticoid receptor activation induces oxidative stress, endothelial dysfunction, inflammation and subsequent fibrosis. 17 Aldosterone-induced PAI-1 increases are partially mediated by transforming growth factor b1. Although ALDO alone induced transforming growth factor b1 weakly, ALDO and transforming growth factor b1 added together produced synergistic effects on PAI-1 production. Therefore, high ALDO levels induced by RAAS activation may amplify RAAS profibrotic actions. 18 Plasma ALDO levels were directly correlated with fibrinogen, D-dimer and PAI-1, whereas elevated ALDO, fibrinogen, D-dimer, prothrombin fragment 1 þ 2 and PAI-1 levels were associated with clinical and/or instrumental evidence of hypertension-related cardiac and renal damage. 19 The relation between high ALDO levels and hypertension has been discussed and studied extensively. This mineralocorticoid hormone has become the designer hormone in essential hypertension. Studies suggest that ALDO contributes extensively to the development of hypertension apart from the classical role of ALDO in primary aldosteronism. The association of ALDO and hypertension is supported by cross-sectional studies that relate plasma ALDO levels to 24-h ambulatory blood pressure monitoring levels and prospective analyses that indicate ALDO as a predictor in the development of hypertension. Moreover, studies confirm the antihypertensive efficacy of ALDO antagonists in treating essential hypertension and that renin activity is not related to BP levels, suggesting an autonomous role of ALDO in causing hypertension that is independent of renin-angiotensin II. 20 The role of inflammation in essential hypertension is broadly investigated. Studies have shown that vascular inflammation could have an important role in the development of hypertension. Renal dysfunction has been proposed as the crucial step in the pathophysiology of essential hypertension. Specifically, arterial and systemic inflammatory processes have been indicated as possible active mediators contributing to the increase of renal damage. 21 In this pathophysiological model, several factors can induce renal vasoconstriction, ischemia and injury. Tubulointerstitial infiltration of inflammatory cells might be the immune response to renal damage. 22 Mainly, macrophages and T cells are recruited into renal parenchyma. 23, 24 On the other side, circulating neutrophils could also increase renal damage in essential hypertension, releasing reactive oxygen species. 25 In the present large retrospective study, hypertensive patients exhibit higher levels of inflammatory and prothrombotic factors as the range of ALDO rises, within normal limits, independently of BP levels. Specifically, patients with high ALDO and low PRA present higher levels of inflammatory and prothrombotic factors. Furthermore, patients with low ALDO and high PRA have the lowest levels of markers compared with the other three groups.
Subclinical inflammation has been implicated as a pathophysiological pathway in many cardiovascular modalities including endothelial dysfunction induced by hypertension. On the other hand, essential hypertension is multifactorial and several interrelations with markers (that is, inflammatory, prothrombotic and so on) have been documented in the past.
To our view, the present study aimed at assessing the association of subclinical inflammatory markers with ALDO and PRA levels, as an expression of different degree of RAAS activation, in never-treated essential hypertensives. The clinical significance of the present study findings is derived from the fact that in a newly diagnosed hypertensive patient with high ALDO levels, the therapeutic approach could potentially differ from that of a patient with low RAAS activation, not only in respect of the BP control but also in respect of the higher risk for endothelial dysfunction. In conclusion, the differences of the markers between the four groups remain significant, except for WBC, after adjustment for other risk factors. These data indicate that ALDO and PRA influence the process of subclinical inflammation involved in increased cardiovascular risk (CVR).
What is known about this topic
Aldosterone (ALDO) is a major component of the renin-angiotensin aldosterone system and it has been recognized as one of the key hormones in the pathophysiology, not only in primary aldosteronism but also in essential hypertension. Recent studies indicate that the pro-inflammatory action of aldosterone or the activation of mineralocorticoid receptors contributes to increased risk for cardiovascular disease.
What this study adds
In the present large retrospective study, hypertensive patients exhibit higher levels of inflammatory and prothrombotic factors as the range of ALDO rises, within normal limits, independently of BP levels. Never-treated essential hypertensive patients with a more activated RAAS (group I high ALDO-low PRA and group II high ALDO-high PRA) present higher levels of inflammatory and prothrombotic markers. 
